Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is the GHRH Receptor? Sermorelin and Tesamorelin Research

Conceptual illustration of a peptide approaching a seven-transmembrane GHRH receptor in a pituitary somatotroph membrane.

GHRHR is the cell-membrane receptor for growth hormone-releasing hormone (GHRH), expressed in the pituitary and coupled to G proteins that activate adenylyl cyclase and support growth hormone synthesis and secretion.[1] This article focuses on the receptor itself, complementing the site’s tesamorelin mechanism article without repeating its molecular dossier or experimental readout lists. GHRHR is a class B G protein-coupled receptor (GPCR) of pituitary somatotropic cells; its natural ligand, GHRH, is a 44-amino-acid hypothalamic peptide.[2] Sermorelin and tesamorelin are GHRHR agonists: they activate the same receptor rather than defining separate receptor types.[3]

What the Receptor Is and Where It Is Expressed

Human GHRHR is annotated as a 423-residue precursor. Its topology includes a signal peptide at residues 1–22, an extracellular domain at 23–130, seven transmembrane helices, and a cytoplasmic C-terminal domain at 379–423. UniProt identifies the pituitary gland as its tissue specificity and the cell membrane as its location.[1] The extracellular region and membrane-spanning bundle provide different parts of the ligand-recognition surface, while the intracellular face engages the signaling machinery.[2]

Receptor defects are associated with isolated growth hormone deficiency type 4 (IGHD4), an autosomal recessive condition involving early, severe growth failure and short stature.[1] This human disease association establishes the receptor’s physiological importance; it does not establish a treatment effect for an agonist.

GHRHR is distinct from the growth hormone secretagogue receptor, also called the ghrelin receptor, where growth hormone-releasing peptides act. Similar terminology therefore does not imply the same molecular target.[3]

How GHRH Docks into the Receptor: ECD, ECLs and the Transmembrane Core

Schematic GHRH receptor with a flexible extracellular domain, three extracellular loops and a peptide N-terminus extending into the seven-helix bundle.

Class B GPCR peptide recognition involves both the extracellular domain (ECD) and the seven-transmembrane domain (7-TMD). The ligand’s C-terminal α-helical region engages the ECD, while its N-terminus reaches into the extracellular face of the transmembrane bundle.[2] These are complementary parts of the binding architecture, not evidence that a static structure establishes the timing of individual binding steps.

The 2.6 Å cryo-EM structure of human GHRHR bound to endogenous GHRH and a Gs heterotrimer contains modeled GHRH residues 1–28 and receptor residues 119–394. The ECD region at residues 25–118 was not resolved in the cryo-EM map and was docked from crystal structure 2XDG, consistent with a flexible, dynamic domain.[2] The ECD’s placement must therefore be distinguished from the directly resolved transmembrane core.

The study describes an extensive interaction network involving all three extracellular loops—ECL1, ECL2 and ECL3—all transmembrane helices except TM4, the ECD–TMD linker, and the ECD. GHRH’s N-terminus inserts deeply into the transmembrane core.[2] Several contacts show how different peptide residues contribute: the Tyr1 hydroxyl hydrogen-bonds with H210 and contacts T213 and W282; Asp3 forms salt bridges with K182; Phe6 stacks against F126 and Y133; and Arg11 forms a salt bridge with D274 and stabilizes the ECL1–ECL2 interface.[2]

GHRH residues beyond position 20 contact the ECD. Removing that domain in the GHRHR(119–423) construct nearly abolished cAMP signaling in HEK293T cells, providing functional support for its contribution to receptor activation.[2] These contacts and deletion results concern endogenous GHRH; they are not analogue-specific binding maps for sermorelin or tesamorelin.

Activation, the TM6 Kink and Gs Coupling

Activated GHRH receptor schematic showing an outward-kinked transmembrane helix and a Gs heterotrimer engaging the intracellular cavity.

The activated receptor has an outward displacement of the cytoplasmic end of TM6, associated with a kink around the conserved Pro6.47-X-X-Gly6.50 motif. This opens an intracellular cavity that accommodates the α5 helix of Gαs, connecting the extracellular ligand-binding architecture to G protein engagement.[2]

Gs contacts transmembrane helices 2, 3, 6 and 7, intracellular loop 2 and helix 8. Two water molecules connect the Gαs C-terminus to the TM7–helix 8 hinge, while Gβ participates in an electrostatic network with intracellular loop 1 and helix 8.[2] Coupling thus involves a broader intracellular interface than the TM6 opening alone.

Mutagenesis links this architecture to function. P336L hampers the TM6 kink, R357C reduces GHRH potency roughly 1,000-fold, and S140P reduces cAMP accumulation more than 7,000-fold in the reported assays.[2] These are receptor-variant effects measured in cells, not differences between peptide products or predictions of human responses.

cAMP/PKA, β-Arrestin and Signal Bias

GHRHR couples to Gs and activates adenylyl cyclase, increasing cAMP.[1] Evidence for the downstream protein kinase A (PKA) step comes from purified rat somatotrophs: GRF stimulated cytosolic PKA activity and growth hormone release dose-dependently, and cAMP synthesis and PKA activation preceded the growth hormone response.[4] Forskolin and membrane-permeant db.cAMP mimicked the growth hormone-releasing effect. Rp.cAMP blocked cytosolic PKA activity and GRF-induced growth hormone release, and the PKA catalytic-subunit inhibitor H89 produced similar inhibition.[4]

Somatostatin at 1 nM suppressed the growth hormone response to GRF without affecting basal or GRF-stimulated PKA activity. Consequently, secretion and PKA activity were not interchangeable readouts under that condition.[4] These experiments used endogenous GRF in a purified rat somatotroph model, not sermorelin or tesamorelin, and did not measure human outcomes.

GHRHR can also recruit β-arrestin2. The structural study tested 25 missense mutants using cAMP and β-arrestin2 recruitment assays; M214V reduced GHRH potency about tenfold and selectively reduced β-arrestin2 recruitment.[2] A cAMP result alone therefore does not describe every measured signaling response.

Receptor identity can itself affect signaling preference. Splice variant 1 (SV1) differs from canonical GHRHR at the N-terminus. Canonical GHRHR predominantly activates Gs, whereas SV1 preferentially couples to β-arrestins. Structural, molecular-dynamics and functional work links this difference to the receptor N-termini.[5] The preference is not an absolute inability to engage Gs: the study also includes a GHRH-bound SV1–Gs structure.[5]

In prostate cancer cells, SV1 expression correlated positively with ERK1/2 phosphorylation and negatively with the cAMP response. The authors proposed constitutive signal bias as a possible mechanism supporting proliferation; those cell-line correlations do not establish a causal clinical effect in patients.[5] Nor do receptor-variant findings establish that either analogue is a biased agonist.

Receptor Down-Regulation: cAMP Feeds Back on Receptor Message

Repeated GHRH stimulation can reduce responsiveness in pituitary cell cultures. In rat pituitary cultures, exposure for as little as four hours lowered GHRHR mRNA dose-dependently. At the reported maximally effective concentrations, mRNA fell to approximately half of control while growth hormone release increased.[6] An increased secretory response and a reduction in receptor message can therefore occur within the same experimental setting.

GHRH pretreatment reduced the subsequent GHRH-stimulated cAMP response to 46% of untreated controls, whereas growth hormone pretreatment did not impair that response. Forskolin reduced receptor mRNA to 37 ± 6% of control, while octreotide did not affect it.[6] The authors concluded that GHRH inhibits production of its own receptor through a receptor-mediated, cAMP-dependent reduction of GHRHR mRNA.[6]

The measured receptor-side endpoint was mRNA, not a direct count of surface receptors or ligand-binding sites. These rat-cell findings do not establish human receptor turnover or analogue-specific desensitization, and they should not be treated as proof that β-arrestin recruitment caused the observed reduction in receptor message.

Sermorelin and Tesamorelin at the Receptor: What Is Established

Sermorelin is GHRH(1–29), a 29-amino-acid peptide representing the first 29 residues of human GHRH. It is described as a GHRHR agonist that mimics full-length GHRH in promoting growth hormone secretion.[7]

Tesamorelin contains the full 44-amino-acid human GRF sequence with a hexenoyl group attached to the N-terminal tyrosine. Its prescription-product label states that, in vitro, it binds and stimulates human GRF receptors with similar potency to endogenous GRF.[8] This is a receptor-level comparison with endogenous GRF, not with sermorelin, and it does not establish equivalent behavior for research materials.

Their relationship is therefore one endogenous ligand and two synthetic analogues acting at GHRHR. The GHRH-bound structure explains how this receptor recognizes and transduces its natural peptide signal, but it does not directly resolve either analogue’s contacts or establish their relative cAMP or β-arrestin responses.[2] No head-to-head sermorelin–tesamorelin receptor study is supplied here; no potency, efficacy or safety ranking is justified.

Chemical identity is also distinct from receptor pharmacology. PubChem records sermorelin as CID 16132413, with molecular formula C149H246N44O42S and molecular weight 3357.9. Those identity data do not provide binding affinity or functional potency.[9]

Evidence Tiers: Cell Lines, Animal Cells, Human Genetics

The structural and receptor-mutagenesis experiments address molecular contacts and signaling in experimental systems. The PKA and receptor-mRNA studies use isolated rat pituitary cells, not whole-animal treatment models. The SV1 findings concern receptor signaling and prostate cancer cell lines. Human GHRHR disease annotations provide a different kind of evidence: an association between receptor defects and inherited growth hormone deficiency.[2][4][6][5][1]

These distinctions matter because receptor activation, downstream signaling, secretion and human outcomes are different endpoints. The evidence establishes receptor architecture and model-specific mechanisms; it does not establish human efficacy or safety for either analogue.

Related research: What Is Sermorelin: GHRH 1-29 Analog; Tesamorelin Mechanism of Action: GHRH Receptor; Tesamorelin.

Research Use Only Disclaimer. This article is for laboratory research and analytical education, not a validated experimental protocol or medical or veterinary advice. Research materials discussed here are not for administration to humans or animals. No dosing, administration, personal compounding, diagnostic, treatment or purchasing guidance is provided.

References

  1. UniProtKB Q02643 — Growth hormone-releasing hormone receptor
  2. Structural basis for activation of the growth hormone-releasing hormone receptor
  3. Growth-hormone-releasing hormone receptor — Wikipedia
  4. Cytosolic protein kinase A mediates the growth hormone-releasing action of GH-releasing factor in purified rat somatotrophs
  5. Constitutive signal bias mediated by the human GHRHR splice variant 1
  6. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels
  7. Sermorelin — Wikipedia
  8. DailyMed — EGRIFTA SV: Description and Mechanism of Action
  9. PubChem — sermorelin identity record